# Treatment of Bronchial Asthma

**Definition of Asthma** • Chronic inflammatory disorder with intermittent narrowing of the airways. • Or a condition characterized by wide variations, over short periods of time, in the resistance to flow in the

intrapulmonary airways.

Factors in the Treatment Strategy Asthma is a <u>chronic</u> condition The goal of therapy is <u>normal function</u> The Condition is <u>heterogeneous</u> in terms of: Cause or trigger mechanism. Extent of bronchoconstriction and Degree of inflammation. The course is <u>unpredictable.</u> Therapy must be <u>individualized.</u>

### **Risk of Not Treating Asthma**

- Poor or no control of the patient's asthma.
- Accelerated decline in the function of the patient's lungs
- Increased number of attacks of asthma.
- Poorer response to therapy if started late.
- Increased mortality from asthma.

## Goals of Therapy in Asthma

- Minimal symptoms even during sleep.
- No, or infrequent, acute episodes.
- No ED visits or missed days in school or work.
- Rare need for beta-agonist inhaler therapy.
- No limitation of activities even sports.
- Peak flow rate variability less than 20%.
- No or minimal adverse effects from drugs.


#### **Pathogenesis**

#### Early Asthmatic Response:

- Allergens can provoke IgE production.
- The tendency to produce IgE is genetically determined.
- **Re-exposure to the allergen causes antigen**antibody interaction on the surface of the mast cells leading to: **Release of stored mediators.** Synthesis of other mediators. Also, activation of neural pathways Prevented by bronchodilators.


# Pathogenesis Late Asthmatic Response:

- 4-5 hours later.
- More sustained phase of bronchoconstriction.
- Influx of inflammatory cells and an increase in bronchial responsiveness.
- The mediators here are cytokines produced by TH2 lymphocytes, especially interleukins 5, 9, and 13.
- These will stimulate IgE production by B lymphocytes, and directly stimulate mucus production.
- Pranary 24 nted by corticosteroids.



Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J: *Harris្តា្នេ៍ន្ Principles of Internal Medicin*e, 17th Edition: http://www.accessmedicine.com


Copyright @ The McGraw-Hill Companies, Inc. All rights reserved.



Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Harrison's Principles of Internal Medicine, 17th Edition: http://www.accessmedicine.com

#### Simplified view of allergic inflammation in the airways.




Source: Brunton LL, Lazo JS, Parker KL: *Goodman & Gilman's The Pharmacological* Basis of Therapeutics, 11th Edition: http://www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.


Lumen

Airway wall

#### Histopathology of a small airway in fatal asthma



Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J: *Harrison's Principles of Internal Medicin*e, 17th Edition: http://www.accessmedicine.com January 24 Copyright © The McGraw-Hill Companies, Inc. All rights reserved.



# **Asthma Triggers**

- Exercise / cold air
- Cigarette smoke
- Stress / anxiety situations
- Animal dander's (cats, dogs etc..)
- Allergens (grass, trees, molds, cockroach)
- Pollutants (sulfur dioxide, ozone, etc...)
- Fumes/toxic substances
- Medications (ASA, NSAID's, others)

# **Diagnosis of Asthma - Subjective**

 Cough - usually in spasms and to the point of vomiting - nighttime worse than daytime.

 Cough may follow exposure to cold air, exercise, a URI (common cold), or allergen

Dyspnea > cough or wheezing > sputum.

Past history of bronchiolitis as a child

Family history of asthma is common

# **Diagnosis of Asthma - Objective**

- Diminished Peak Expiratory Flow Rate (PEFR)
- Reduced mean and Forced Expiratory Flow Rate (FEFR)
- Reversibility with Bronchodilators
- Heightened response to Methacholine Test.
- Increase in expired Nitric Oxide
- Increase in Inflammatory Mediators and their metabolic products in body fluids

# **Myths and Misconceptions**

✓ Patient <u>and</u> physician "Steroid-o-phobia".

✓ Asthma is an emotional illness.

✓ Asthma is an acute disease.

✓ Asthma medications are addictive.

 Asthma medications become ineffective if they are used regularly.

**Asthma is not a fatal illness / It does not kill.** January 24 Munir Gharaibehm MD, PhD, MHPE Survey of the changing therapy of asthma by decade



#### Aminophylline, Epinephrine, Ephedrine



Beta-agonists, Theophyllines, Beclomethasone, Cromolyn, Ipratropium Survey of the changing therapy of asthma by decade <u>1980's</u>

Beta-agonists, Inhaled Corticosteroids, Cromolyn, Ipratropium

<u>1990's</u>

#### Inhaled Corticosteroids, Betaagonists, Theophylline, Leukotriene Inhibitors


18

January 24

Survey of the changing therapy of asthma by decade 2000's

# Corticosteroids + LABA, LTRAs, Theophylline, Cromolyn, Ipratropium, Tiotropium 2010's

Prevention including gene therapy.



Source: Katzung BG, Masters SB, Trevor AJ: *Basic & Clinical Pharmacology,* 11th Edition: http://www.accessmedicine.com <sup>January 24</sup> Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Step-wise approach to asthma therapy				OCS
			LABA	LABA
		LABA	ICS	ICS
	ICS Low dose	ICS Low dose	High dose	High dose
Short-acting $\beta_2$ -agonist as required for symptom relief				
Mild intermittent	Mild persistent	Moderate persistent	Severe persistent	Very severe persistent

Source: Fauci AS, Kasper DL, Braunwald E, Hauser SL, Longo DL, Jameson JL, Loscalzo J: *Harrison's Principles of Internal Medicin*e, 17th Edition: http://www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Inhaled Long-acting Beta-2 Agonists (LABA) Inhaled Corticosteroids(ICS) (OCS) oral Corticosteroids **Relievers / Controllers** 

- Quick relief medications:
  - Inhaled Short acting Beta-2 Agonists
  - Inhaled Anticholinergics
  - Systemic Corticosteroids

#### Long-term control medications:

- **Topical (inhaled) Corticosteroids**
- Inhaled Cromolyn Na and Nedocromil
- Oral Methylxanthines (Theophyllines)
- Inhaled Long-acting Beta-2 Agonists (LABA)
- Januar Aral Leukotriene modifiers (LTRA)